Vismodegib for the treatment of basal cell skin cancer

Poggi, L; Kolesar, Jill

doi:10.2146/ajhp120311

Cited by 21 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a new treatment option for metastatic or locally advanced disease not amenable to surgery or radiotherapy became available. Vismodegib is a small‐molecule inhibitor of SMO . Most BCCs contain a genetic alteration in the hedgehog signalling pathway, resulting in aberrant pathway activation and uncontrolled proliferation of basal cells.…”

Section: Resultsmentioning

confidence: 99%

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

et al. 2016

View full text Add to dashboard Cite

The incidence of basal cell carcinoma (BCC) has risen three- to fourfold over the last 30 years and is expected to continue to increase with ageing of the population. Although BCC has a good prognosis, it causes significant morbidity and has an important impact on the public health budget due to direct treatment costs. Based on the existing evidence, a systematic evaluation of the World Health Organization criteria was performed to determine whether earlier detection of BCC could reduce morbidity and cost. BCC slowly increases in size, with a median increase in diameter of 0·5 mm over 10 weeks. There is an important delay in diagnosis ranging from 19 to 25 months. In several studies BCC size was the main determinant of treatment cost, surgical complexity, reconstruction technique and the specific surgical procedure performed, such as Mohs micrographic surgery or surgical excision. One study showed that size also seems to affect the cost per treatment for other nonsurgical options. The use of vismodegib, an inhibitor of the hedgehog pathway, is confined to locally advanced or metastatic BCC. Delays in diagnosis and appropriate treatment are the most important underlying causes in the occurrence of giant BCC and/or BCC with metastasis. Although the latter represent only a very small fraction of all BCCs, the majority of them are located in the facial region. The available data point to a slow increase in the size of BCCs over time. Size is one of the major determinants in choice of treatment and the associated cost, especially for facial BCC. Therefore we conclude that current data support early detection and adequate management of BCCs on the face.

show abstract

Section: Resultsmentioning

confidence: 99%

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

et al. 2016

View full text Add to dashboard Cite

show abstract

“…(9)(10)(11)(12) Currently, the Smo inhibitors erismodegib and saridegib are in clinical trials (13,14) and the Smo inhibitor vismodegib was approved by the US Food and Drug Administration for the treatment of unresectable or metastatic basal cell carcinomas of the skin in 2012. (15) Thus, the Hh signaling pathway is a therapeutic target in some cancers. However, in GBC, the status of Hh signaling is still unknown.…”

mentioning

confidence: 99%

“…In addition, a link between cancer stem cells and Hh signaling activation has been reported . Currently, the Smo inhibitors erismodegib and saridegib are in clinical trials and the Smo inhibitor vismodegib was approved by the US Food and Drug Administration for the treatment of unresectable or metastatic basal cell carcinomas of the skin in 2012 . Thus, the Hh signaling pathway is a therapeutic target in some cancers.…”

mentioning

confidence: 99%

Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer

et al. 2014

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is a particularly deadly type of cancer with a 5-year survival rate of only 10%. New effective therapeutic strategies are greatly needed. Recently, we have shown that Hedgehog (Hh) signaling is reactivated in various types of cancer and is a potential therapeutic target. However, little is known about the biological significance of Hh signaling in human GBC. In this study, we determined whether Hh signaling could be a therapeutic target in GBC. The Hh transcription factor Gli1 was detected in the nucleus of GBC cells but not in the nucleus of normal gallbladder cells. The expression levels of Sonic Hh (Shh) and Smoothened (Smo) in human GBC specimens (n = 37) were higher than those in normal gallbladder tissue. The addition of exogenous Shh ligand augmented the anchor-dependent and anchor-independent proliferation and invasiveness of GBC cells in vitro. In contrast, inhibiting the effector Smo decreased the anchor-dependent and anchor-independent proliferation. Furthermore, the suppression of Smo decreased GBC cell invasiveness through the inhibition of MMP-2 and MMP-9 expression and inhibited the epithelial–mesenchymal transition. In a xenograft model, tumor volume in Smo siRNA-transfected GBC cells was significantly lower than in control tumors. These results suggest that Hh signaling is elevated in GBC and may be involved in the acquisition of malignant phenotypes, and that Hh signaling may be a potential therapeutic target for GBC.

show abstract

“…10 Several new medications are available for skin cancer, which increases treatment options but could also lead to higher costs. [65][66][67] Skin cancer also results in significant costs beyond those related to treatment. Annual costs associated with lost workdays and restricted-activity days are estimated at $76.8 million for NMSC and $29.4 million for melanoma.…”

Section: Economic Burden Of Skin Cancermentioning

confidence: 99%

Forekomsten av føflekkreft øker igjen

Veierød¹

2015

Tidsskriftet

View full text Add to dashboard Cite

Skin cancer is the most commonly diagnosed cancer in the United States, yet most cases are preventable. Every year in the United States, nearly 5 million people are treated for skin cancer, at an estimated cost of $8.1 billion. Melanoma, the most deadly form of skin cancer, causes nearly 9,000 deaths each year. Despite recent efforts to address risk factors, skin cancer rates continue to rise.While those with lighter skin are more susceptible, anyone can get skin cancer-and it can be serious, even deadly. As a skin oncologist who worked in this field for many years, I have cared for both young and old with skin cancers. Almost all of the conditions were caused by unnecessary ultraviolet (UV) radiation exposure, usually from excessive time in the sun or from the use of indoor tanning devices.It is alarming that every year, nearly one out of every three young white women aged 16-25 engages in indoor tanning. It's important to shatter the myth that tanned skin is a sign of health. And a "base" tan is not a "safe" tan. Tanned skin is damaged skin. Understanding the risk of UV exposure is crucial to protecting ourselves and our loved ones.That is why The Surgeon General's Call to Action to Prevent Skin Cancer is important for all of us. It outlines action steps we can all take-as individuals, parents, educators, employers, policy makers, health care professionals, and communities-to reverse this alarming trend.As a nation, we can all do more to address skin cancer as a serious public health challenge. I urge everyone to find out more about the risk of skin cancer-and what we all can do to prevent it.The rates of skin cancer in our nation are increasing, creating a serious public health concern we cannot ignore. As both a medical doctor and a public health official, I see that now is the time for a comprehensive approach to prevent skin cancer, bringing together community partners, business leaders, government agencies, and individuals for a common cause. As a dermatologist, I consider myself fortunate to be a part of this effort and am proud to release this Call to Action to Prevent Skin Cancer.By acknowledging that most skin cancers can be prevented and bringing together partners with a unified, dynamic approach, we are taking concrete steps to support a healthier country. We know there are many strategies that work to protect us from ultraviolet (UV) radiation from the sun, and we need to use them. For example, we recommend that communities provide shade in recreational and play areas to help protect children from overexposure to UV radiation, that businesses increase availability of sun protection for outdoor workers, that policy makers promote policies for shade planning in land use development, and that health providers counsel patients on the importance of using sun protection.Each day, thousands of teens are exposing themselves, unprotected, to harmful UV radiation from tanning beds, but only 10 states currently have laws in place to prevent this practice for youth younger than age 18 years. Together, we must c...

show abstract

Vismodegib for the treatment of basal cell skin cancer

Cited by 21 publications

References 15 publications

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening

Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer

Forekomsten av føflekkreft øker igjen

Contact Info

Product

Resources

About